Productwise 3-2-1 - Consumer Protection mondaq.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mondaq.com Daily Mail and Mail on Sunday newspapers.
To embed, copy and paste the code into your website or blog:
On 11 March 2021 the UK government announced a consultation with the intention of reviewing and strengthening the UK’s product safety laws to ensure that they are fit for the 21st century. Business Minister Paul Scully spoke of a “new, modern product safety regime which will unleash the creative potential of our businesses while keeping consumers safe”.
Whilst product safety is the focus, the review will also consider how the Consumer Protection Act 1987 (CPA) is working in practice today. This legislation, which implements the 1984 European Product Liability Directive (PLD), came into force over 30 years ago, and provides a strict liability regime for the recovery of civil damages with a “consumer expectations” test. The PLD has itself been under review by the European Commission since 2016, however, post Brexit, the UK is taking the opportunity to shape its own legislation considering where responsibility sho
MAJOR MARKET COMPARISON OF KEY COVID-19 LEGISLATION
As pharmaceutical companies worldwide race to supply vaccines
and therapeutics to fight the spread of COVID-19, understanding the
laws and regulations that could impact parties involved in the
COVID-19 pandemic supply chain is increasingly important. This
article provides an overview and comparison of legislation relevant
to manufacturers, suppliers, distributors, and health professionals
involved in the response to the COVID-19 pandemic in each of the
United States ( US ), European Union ( EU ),
United Kingdom ( UK ), and People s Republic of China
( PRC ), including measures to ensure (1) immunity from
COVID-19 countermeasure liability; (2) government ability to direct
(or redirect) resources; (3) emergency use authorizations; (4)
To print this article, all you need is to be registered or login on Mondaq.com.
Historically pharmaceutical companies turned to contract
manufacturers for achieving efficiencies in cost, capacity and
time-to-market, or to obtain specific expertise not available
in-house. However, the increment in outsourcing of manufacture is
driven, at least in part, by the fact that contract manufacturers
have increasingly developed innovative proprietary processes and
implemented technology that may well surpass that available at the
pharmaceutical client s own facilities. Moreover, nowadays few
pharmaceuticals are made in dedicated plants and key intermediates
and active compounds can be made in general-purpose plants.